Vascular disrupting agents in clinical developmentHINNEN, P; ESKENS, F. A. L. M.British journal of cancer. 2007, Vol 96, Num 8, pp 1159-1165, issn 0007-0920, 7 p.Article

Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models : facing the challenge of a proper study designESKENS, F. A. L. M; VERWEIJ, J.Critical reviews in oncology/hematology. 2000, Vol 34, Num 2, pp 83-88, issn 1040-8428Article

Farnesyl transferase inhibitors : current developments and future perspectivesESKENS, F. A. L. M; STOTER, G; VERWEIJ, J et al.Cancer treatment reviews. 2000, Vol 26, Num 5, pp 319-332, issn 0305-7372Article

Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagusPOLEE, M. B; TILANUS, H. W; ESKENS, F. A. L. M et al.Annals of oncology. 2003, Vol 14, Num 8, pp 1253-1257, issn 0923-7534, 5 p.Article

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I studyHAMBERG, P; BOERS-SONDEREN, M. J; VAN DER GRAAF, W. T. A et al.British journal of cancer. 2014, Vol 110, Num 4, pp 888-893, issn 0007-0920, 6 p.Article

Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent gliomaVAN DEN BENT, M. J; PRONK, L; SMITT, P. A. E. S et al.Journal of neuro-oncology. 1999, Vol 44, Num 1, pp 59-64, issn 0167-594XArticle

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumoursESKENS, F. A. L. M; TRESCA, P; TOSI, D et al.British journal of cancer. 2014, Vol 110, Num 9, pp 2170-2177, issn 0007-0920, 8 p.Article

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor abt-510 with 5-fluorouracil and leucovorin : A safe combinationHOEKSTRA, R; DE VOS, F. Y. F. L; ESKENS, F. A. L. M et al.European journal of cancer (1990). 2006, Vol 42, Num 4, pp 467-472, issn 0959-8049, 6 p.Article

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumorsGIETEMA, J. A; HOEKSTRA, R; ESKENS, F. A. L. M et al.Annals of oncology. 2006, Vol 17, Num 8, pp 1320-1327, issn 0923-7534, 8 p.Article

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumoursAWADA, A; ESKENS, F. A. L. M; VERWEIJ, J et al.European journal of cancer (1990). 2002, Vol 38, Num 17, pp 2272-2278, issn 0959-8049, 7 p.Article

Pancreatic islet cell tumor producing vasoactive intestinal polypeptide and calcitoninESKENS, F. A. L. M; ROELOFS, E. J. M; HERMUS, A. R. M. M et al.Anticancer research. 1997, Vol 17, Num 6D, pp 4667-4670, issn 0250-7005Article

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumoursKLTZEN, J. J. E. M; DE JONGE, M. J. A; LAMERS, C. H. J et al.European journal of cancer (1990). 2009, Vol 45, Num 10, pp 1764-1772, issn 0959-8049, 9 p.Article

A phase I dose escalation study off BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursESKENS, F. A. L. M; MOM, C. H; DE VRIES, E. G. E et al.British journal of cancer. 2008, Vol 98, Num 1, pp 80-85, issn 0007-0920, 6 p.Article

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumoursESKENS, F. A. L. M; DUMEZ, H; HOEKSTRA, R et al.European journal of cancer (1990). 2003, Vol 39, Num 7, pp 917-926, issn 0959-8049, 10 p.Article

Septic shock caused by group G β-haemolytic streptococci as presenting symptom of acute myeloid leukaemiaESKENS, F. A. L. M; VERWEIJ, P. E; MEIS, J. F. G. M et al.Netherlands journal of medicine. 1995, Vol 46, Num 3, pp 153-155, issn 0300-2977Conference Paper

Systemic treatment in hepatocellular carcinoma; 'A small step for man...'WITJES, C. D. M; VERHOEF, C; VERHEUL, H. M. W et al.Netherlands journal of medicine. 2009, Vol 67, Num 3, pp 86-90, issn 0300-2977, 5 p.Article

First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer : a phase II studyVAN MEERTEN, E; ESKENS, F. A. L. M; VAN GAMEREN, E. C et al.British journal of cancer. 2007, Vol 96, Num 9, pp 1348-1352, issn 0007-0920, 5 p.Article

Temozolomide chemotherapy in recurrent oligodendrogliomaVAN DEN BENT, M. J; KEIME-GUIBERT, F; BRANDES, A. A et al.Neurology. 2001, Vol 57, Num 2, pp 340-342, issn 0028-3878Conference Paper

Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitorESKENS, F. A. L. M; LEVITT, N. C; SPARREBOOM, A et al.Clinical cancer research. 2000, Vol 6, Num 2, pp 431-433, issn 1078-0432Article